According to the latest interim analysis of the landmark KATHERINE trial, patients with HER2-positive early breast cancer who had residual invasive disease after NACT have improved survival when they receive adjuvant T-DM1 therapy after surgery [7]. This evidence concerns the gene ERBB2 and breast cancer.